LLY News
Eli Lilly and Company
$1,208.74
+$42.23(+3.62%)
60
Overall
45
Value
66
Tech
71
Quality
Market Cap
$1.14T
Volume
3.15M
52W Range
$783.85 - $1,292.65
Target Price
$1,357.04
LLY news: the latest Eli Lilly and Company headlines, press releases and market updates, newest first.
Latest LLY News
- Lilly’s Tersolisib Food‑Effect Study Marks Quiet But Important Pipeline ProgressTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 14, 2026
- BMO Capital Sticks to Its Buy Rating for Eli Lilly & Co (LLY)TipRanks Auto-Generated Intelligence Newsdesk · Oct 12, 2026
- RBC Capital Sticks to Their Buy Rating for Eli Lilly & Co (LLY)TipRanks Auto-Generated Intelligence Newsdesk · Oct 12, 2026
- Morgan Stanley Reaffirms Their Buy Rating on CSL (CMXHF)TipRanks Auto-Generated Intelligence Newsdesk · Oct 12, 2026
- Eli Lilly (LLY) Stock: Why Taking Profits Could Make Sense Ahead of 2027Ivo Kolchev · Oct 11, 2026
- Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Legend Biotech (LEGN) and Bristol-Myers Squibb (BMY)TipRanks Newsroom · Oct 9, 2026
- Macquarie Keeps Their Hold Rating on CSL (CMXHF)TipRanks Auto-Generated Intelligence Newsdesk · Oct 9, 2026
- Lilly’s Oral Orforglipron Trial Targets Early Obesity Risks, Raising the Stakes in Weight-Loss PharmaTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 8, 2026
- Eli Lilly Quietly Expands Its Alzheimer’s Pipeline With New Early-Stage TrialTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 8, 2026
- Eli Lilly Tests Obesity Drug Eloralintide With Birth Control: What Investors Should WatchTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 8, 2026
- Analysts Conflicted on These Financial Names: Ally Financial (ALLY) and Bank of Queensland (OtherBKQNF)TipRanks Newsroom · Oct 7, 2026
- Eltrekibart Phase 1 Completion: What Eli Lilly’s Latest Trial Means for LLY InvestorsTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 6, 2026
- Lilly’s New Basal Insulin Candidate Clears Key Early Trial MilestoneTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 6, 2026
- Analysts Offer Insights on Financial Companies: Aon (AON) and Ally Financial (ALLY)TipRanks Newsroom · Oct 6, 2026
- Eli Lilly Stock (LLY) Gains on Regulatory Win for Experimental Cancer DrugJoel Baglole · Oct 5, 2026
- BioTech TRex Bio Set to Roar Onto Nasdaq With $133M IPODavid Craik · Oct 5, 2026
- CSL (CMXHF) Gets a Buy from Ord MinnettTipRanks Auto-Generated Intelligence Newsdesk · Oct 4, 2026
- Eli Lilly & Co (LLY) Gets a Buy from RBC CapitalTipRanks Auto-Generated Intelligence Newsdesk · Oct 3, 2026
- Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Sagimet Biosciences, Inc. Class A (SGMT) and Jade Biosciences (JBIO)TipRanks Newsroom · Oct 1, 2026
- Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (OtherSNYNF), Sagimet Biosciences, Inc. Class A (SGMT) and Eli Lilly & Co (LLY)TipRanks Newsroom · Oct 1, 2026
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | LLY | $1,208.74 | +3.6% | 3.15M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |